Table 1c Results from combination studies with APR-246 and cisplatin in primary ovarian cancer cells

From: APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells

Patient number

Histological description

p53 status

Combination APR-246 and cisplatin

1

Serous adenocarcinoma, grade 2

P153H fs 180* (hom.) (‘p53 null’)

SS

2

Serous adenocarcinoma, grade 3

C135A fs 169* (het.)

SS

3

Serous adenocarcinoma

Y220C (hom.)

SS

4

Poorly differentiated adenocarcinoma

wt p53

SS

5

Adenocarcinoma

Q165* (het.)

SS

  1. Abbreviations: hom., homozygous; het., heterozygous; *, stop codon; fs, frame shift; ‘p53 null’, no full-length p53; SS, strong synergy (CI<0.5).
  2. FMCA assay was used for measurement of cell viability. CI was calculated using Additive model. It should be noted that the sequencing method used (Sanger sequencing and Single Strand Conformation Analysis) cannot distinguish between homozygous and hemizygous mutations. Also, ‘het.’ refers to that both wt p53 and mut p53 are found in the sample. This can either be due to heterozygosity or to a presence of cells with different p53 status, which is not common in cancer cell lines but may occur in primary cancer cells
Back to article page